At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Saline +1 moredrug
Likely dose
Saline 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata
In Brief
A clinical study evaluating Saline and Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine for HIV Positive and 3 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Positive, Anal Condylomata, Anal Warts, HIV Infections
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2009
Primary CompletionJul 2011
TodayJul 2026
First PostedJul 20, 2009
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.9 years ago
Interventions
Salinedrug
0.5 ml
Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccinedrug
0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.